Expanded NIPT for Pregnancy Complications

a study on Fetal Growth Restriction Preeclampsia Pregnancy Eclampsia

Summary

Eligibility
for females ages 18-60 (full criteria)
Location
at San Francisco, California
Dates
study start
estimated completion
Principal Investigator
by Nasim Sobhani, MD
Headshot of Nasim Sobhani
Nasim Sobhani

Description

Summary

This study evaluates the utility of expanded panel non-invasive prenatal testing (NIPT) in detecting confined placental mosaicism of rare autosomal trisomies among pregnancies with placentally-mediated complications, including fetal growth restriction and severe preeclampsia.

Official Title

The Role of Expanded Panel Non-Invasive Prenatal Testing in Identifying Rare Autosomal Trisomies in Pregnancies With Placentally-Mediated Complications

Keywords

Fetal Growth Restriction, Preeclampsia Severe, Pre-Eclampsia, Fetal Growth Retardation, Expanded panel cell free DNA testing (non-invasive prenatal testing), Placental biopsy, Umbilical cord blood, Severe preeclampsia, Low PAPP-A

Eligibility

You can join if…

Open to females ages 18-60

  • For fetal growth restriction cohort: diagnosis of early onset (< 34 weeks) severe fetal growth restriction, defined as estimated fetal weight less than 10th percentile with abnormal umbilical artery Dopplers OR estimated fetal weight less than 5th percentile alone OR biometric size at least 14 days behind expected dates
  • For severe preeclampsia cohort: diagnosis of early onset (< 34 weeks) preeclampsia with severe features, diagnosed by ACOG criteria
  • For low PAPP-A cohort, diagnosis of low PAPP-A levels (pregnancy associated plasma protein A), defined as less than 0.2 multiples of the median
  • For healthy cohort, normal pregnancy with no evidence of maternal, obstetrical, or fetal complications

You CAN'T join if...

Location

  • UCSF accepting new patients
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Nasim Sobhani, MD
    Dr. Nasim Sobhani is a perinatologist, an obstetrician who specializes in care during high-risk pregnancies. She provides comprehensive care for women with preexisting conditions that can affect pregnancy and for women with pregnancy-specific health conditions. She also cares for developing fetuses when genetic or structural conditions have been diagnosed in utero.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04311749
Study Type
Observational
Participants
Expecting 200 study participants
Last Updated
Contact us about this trial